Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2010 1
2012 2
2013 3
2014 3
2015 2
2016 1
2017 1
2018 3
2019 2
2020 3
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

20 results
Results by year
Filters applied: . Clear all
Page 1
MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling.
Venkatesh D, O'Brien NA, Zandkarimi F, Tong DR, Stokes ME, Dunn DE, Kengmana ES, Aron AT, Klein AM, Csuka JM, Moon SH, Conrad M, Chang CJ, Lo DC, D'Alessandro A, Prives C, Stockwell BR. Venkatesh D, et al. Among authors: o brien na. Genes Dev. 2020 Apr 1;34(7-8):526-543. doi: 10.1101/gad.334219.119. Epub 2020 Feb 20. Genes Dev. 2020. PMID: 32079652 Free PMC article.
EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells.
Dillard C, Kiyohara M, Mah V, McDermott SP, Bazzoun D, Tsui J, Chan AM, Haddad G, Pellegrini M, Chang YL, Elshimali Y, Wu Y, Vadgama JV, Kim SR, Goodglick L, Law SM, Patel DD, Dhawan P, O'Brien NA, Gordon LK, Braun J, Lazar G, Wicha MS, Wadehra M. Dillard C, et al. Among authors: o brien na. Mol Cancer Ther. 2020 Aug;19(8):1682-1695. doi: 10.1158/1535-7163.MCT-19-0850. Epub 2020 May 25. Mol Cancer Ther. 2020. PMID: 32451329 Free PMC article.
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
O'Brien NA, McDermott MSJ, Conklin D, Luo T, Ayala R, Salgar S, Chau K, DiTomaso E, Babbar N, Su F, Gaither A, Hurvitz SA, Linnartz R, Rose K, Hirawat S, Slamon DJ. O'Brien NA, et al. Breast Cancer Res. 2020 Aug 14;22(1):89. doi: 10.1186/s13058-020-01320-8. Breast Cancer Res. 2020. PMID: 32795346 Free PMC article.
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
McDermott MS, Browne BC, Conlon NT, O'Brien NA, Slamon DJ, Henry M, Meleady P, Clynes M, Dowling P, Crown J, O'Donovan N. McDermott MS, et al. Among authors: o brien na. Mol Cancer. 2014 Jun 24;13:157. doi: 10.1186/1476-4598-13-157. Mol Cancer. 2014. PMID: 24958351 Free PMC article.
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.
Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, O'Brien NA, Roxanis I, Li JL, Bridge E, Finn R, Siamon D, McGowan P, Duffy MJ, O'Donovan N, Crown J, Kong A. Canonici A, et al. Among authors: o brien na. Oncotarget. 2013 Oct;4(10):1592-605. doi: 10.18632/oncotarget.1148. Oncotarget. 2013. PMID: 24009064 Free PMC article.
20 results